For patients with locally advanced cervical cancer (LACC), concurrent radiochemotherapy including brachytherapy (BT) is the standard therapy, leading to good oncologic results \[[@CR1]--[@CR3]\]. The reported absolute risk of developing grade 3--4 (G3--4) genitourinary (GU) or gastrointestinal (GI) fistulae through definitive radiation therapy including standard BT with dose prescription to point A is around 9% (overall G3--4 toxicity 30%) \[[@CR4]\]. Within the last few years, modern radiotherapy techniques have been introduced into the treatment of LACC. These include magnetic resonance (MR) image-guided adaptive brachytherapy (IGABT) \[[@CR5]\] with dose prescription individualised to the target at the time of BT. In a recently published cohort of 731 patients, the overall actuarial rate of G3--4 GI and GU toxicity after definitive radiochemotherapy and IGABT was 11% at 5 years \[[@CR6], [@CR18]\]. A previous publication from our centre on 156 patients in whom systematic IGABT was performed reported only 2/156 fistula events \[[@CR5]\]. Despite excellent overall local tumour control results, several series \[[@CR5], [@CR7], [@CR8]\] still observed relatively high rates of distant recurrences after IGABT, especially in patients with advanced stage (stage III/IV) and/or nodal disease \[[@CR6]\]. These distant metastases require cytotoxic treatment.

Patients with recurrent cervical cancer (RecCC), depending on the site of relapse (local, distant), have been treated by systemic chemotherapy (CHT), typically with paclitaxel-containing regimes. Since 2014, the use of bevacizumab (BEV) in combination with systemic CHT for the treatment of recurrent or metastatic cervical cancer has become common. It has been shown that the addition of BEV was associated with a significant increase in progression-free and overall survival \[[@CR9]\]. However, it has also been reported that CHT+BEV is associated with an increased risk of fistula formation when compared to CHT alone in patients with cervical cancer \[[@CR10]\], even in the absence of radiation treatment. In a subset analysis of the Gynecologic Oncology Group trial (GOG 240) published in abstract form \[[@CR11]\], it was observed that among the patients who developed GI vaginal fistula, 100% had received prior pelvic radiation, some including standard brachytherapy. However, little is known about the risk factors for fistula formation in the presence of BEV. This study aims to evaluate whether patients with RecCC treated initially by concurrent radiochemotherapy and IGABT have an increased risk for GI and GU fistula formation after CHT+BEV treatment.

Materials and methods {#Sec1}
=====================

Patients {#Sec2}
--------

Consecutive patients diagnosed with RecCC who were treated between 2009 and 2014 in our institution were enrolled in this study. Clinical data were obtained using available tumour databases and by electronic chart review. The 2009 International Federation of Gynecology and Obstetrics (FIGO) classification system was used \[[@CR12]\]. Eligible patients had recurrence of a formerly locally advanced cervical cancer that had been initially treated by definitive concurrent radiochemotherapy including IGABT in our institution. Patients treated initially with surgery or those with primary metastatic disease were not eligible.

Tumour status was assessed, the presence of GU and GI fistula identified, and survival and follow-up times were recorded. Risk factors for fistula development including comorbidities (diabetes, arterial hypertension, peripheral vascular disease, thromboembolic events), previously performed bowel surgery, minor interventions/biopsy/major pelvic surgery after RecCC and number of treatment cycles were documented.

The primary endpoint was to document the frequency of fistula events in both groups (CHT or CHT+BEV) in this mono-institutional series.

The Ethics Committee of our institution gave approval prior to initiation of the study (IRB approval number: 1996/2015). All patients consented to treatment according to institutional guidelines, as well as to anonymized assessments and analysis of data and outcome of therapy. Records were anonymized and de-identified prior to analysis.

Treatment {#Sec3}
---------

### Initial treatment {#Sec4}

All patients received definitive concurrent radiochemotherapy. Radiotherapy consisted of external beam radiotherapy (EBRT) concurrent with weekly cisplatin-based CHT (usually cisplatin 5 × 40 mg/m^2^ body surface area) and IGABT. The maximally allowed duration of radiation therapy was 50 days in total.

### External beam radiotherapy {#Sec5}

EBRT was delivered using three-dimensional conformal techniques or intensity-modulated radiation therapy. The clinical target volume (CTV) irradiated through EBRT consisted of the tumour, entire uterus, bilateral parametria, upper vagina (if no vaginal involvement had been present) and the pelvic lymph nodes. In case of lymph node involvement of the common iliac or para-aortic (PAN) lymph nodes (as diagnosed by positron-emission tomography/CT \[PET-CT\] or laparoscopic staging lymphadenectomy), para-aortic radiotherapy was performed. The prescribed dose was 45 Gy at 1.8 Gy per fraction. Grossly involved lymph nodes, if not surgically removed, were treated with an additional boost (range 55--60 Gy).

### Image-guided adaptive brachytherapy {#Sec6}

Systematically, MRI-based IGABT was performed in all patients diagnosed with LACC with definitive intent. The high-risk CTV (HRCTV) and/or the intermediate-risk CTV (IRCTV) was contoured according to Gyn GEC-ESTRO Recommendations I \[[@CR13]\]. Organs at risk (OARs) were contoured: rectum, sigmoid colon and urinary bladder. Dose--volume histogram (DVH) parameters for the HRCTV, IRCTV and OARs were calculated and reported according to Gyn GEC-ESTRO Recommendations II \[[@CR14]\]. Dose prescription for target and dose constraints for OARs were applied according to our institutional guidelines \[[@CR5]\]. Our planning aim was ≥85 Gy to 90% of the HRCTV (D~90~). This total EQD2 (equivalent dose in 2 Gy per fraction) from EBRT and BT was calculated using an a/β of 10 Gy for tumour (EQD2~10~) and 3 Gy for OARs (EQD2~3~) \[[@CR15]\].

Follow-up {#Sec7}
---------

All patients were followed-up in a joint programme by a gynaecologic oncologist and a radiation oncologist specialised in gynaecologic malignancies. Regular follow-up included clinical examination, blood analysis and imaging. Complete remission after initial treatment was defined as the absence of disease in the cervix (uterus), upper vagina, parametrium and regional lymph nodes, as verified by clinical examination, abdominal and thoracic imaging, and biopsy as appropriate. Patients were followed-up every 3 to 4 months for the first 3 years, every 6 months for the following 2 years and annually up to 10 years and beyond thereafter. Follow-up was performed at our institution using standardized questionnaires and assessment forms.

If recurrent disease was suspected, restaging by CT scans of the thorax and abdomen as well as MRI of the pelvis was performed. Whenever possible, recurrent disease was confirmed by biopsy and PET-CT was additionally performed.

Recurrence treatment {#Sec8}
--------------------

### Chemotherapy/bevacizumab {#Sec9}

Within this study, all patients were treated by either CHT or CHT+BEV. In addition, salvage surgery was performed in selected cases. CHT consisted of paclitaxel in combination with cisplatin (*n* = 18), with carboplatin (*n* = 2), or with topotecan (*n* = 5). Alternatively, selected patients received cisplatin in combination with topotecan (*n* = 9) or carboplatin with docetaxel (*n* = 1). CHT was administered until progression, complete response or treatment-limiting toxicity occurred. Starting 2013, most patients received BEV in addition to CHT (*n* = 10). Thereafter, patients were again followed-up according to the institution's follow-up program. In a few cases, salvage surgery or radiotherapy of metastases was performed in the presence of oligometastases in lung, liver or periaortic nodes.

Statistical analysis {#Sec10}
--------------------

Time-to-event analyses were computed using the Kaplan--Meier method and log-rank test, with and IBM SPSS 23.0 for MAC (SPSS 23.0, IBM Inc., Armonk, NY, USA). Time intervals for survival analyses were calculated from the date of biopsy to the date of event or last follow-up. Patients lost to follow-up were censored at the time of last follow-up.

Descriptive statistic values are given as mean (standard deviation, SD). *T*-tests and χ^2^ tests were used to compare patients' characteristics and risk factors for fistula formation between groups. *P*-values \<0.05 were considered statistically significant. Overall survival was analysed using the log-rank test.

Results {#Sec11}
=======

A total of 35 patients were included in this study. Patients' and treatment characteristics are shown in Table [1](#Tab1){ref-type="table"}. There were no fistulae at the time of relapse diagnostic. CHT was received by 25 patients and 10 patients received CHT+BEV. Patient characteristics and treatment modalities in the both groups were similar. All 10 patients in the CHT +BEV group had undergone interstitial IGABT as opposed to 21/25 in the CHT group (*p* = 0.18).Table 1Patient characteristics for the whole group (*N* = 35) and broken down by subsequent treatment, i. e. chemotherapy only or chemotherapy plus bevacizumabVariable*N* total (%)CHT (*N* = 25)\
*N* (%)CHT+BEV (*N* = 10)\
*N* (%)**Initial stage**IB4 (11)3 (12)1 (10)IIB18 (52)15 (60)3 (30)IIIA--IIIB8 (22)4 (16)4 (40)IVA3 (9)3 (12)0IVB2 (6)02 (20)**Histology**Squamous cell carcinoma27 (77)20 (80)7 (70)Adenocarcinoma or adeno-squamous8 (23)5 (20)3 (30)**Grade**G13 (9)2 (8)1 (10)G214 (40)9 (36)5 (50)G313 (37)10 (40)3 (30)Not evaluated5 (14)4 (16)1 (10)**Median age (years)**51 (32--78)53 (32--78)49 (32--64)**ECOG**021 (60)14 (56)7 (70)112 (34)10 (40)2 (20)22 (6)2 (4)1 (10)**Comorbidities***Diabetes*Yes2 (6)1 (4)1 (10)No33 (94)24 (96)9 (90)*Hypertension*Yes12 (34)7 (28)5 (50)No23 (66)18 (72)5 (50)*GI surgery*Yes2 appendectomy, 3 bowel resection (14)4 (16)1 bowel resection (10)No30 (86)21 (84)9 (90)*Thromboembolic event*Yes6 (17)2 (8)4 (40)No29 (83)23 (92)6 (60)**Primary treatment**--CHTCHT+BEVEBRT dose (Gy)454545EBRT pelvis (*n*)20155EBRT extended-field (*n*)15105EBRT IMRT/VMAT (*n*)6 (17)06 (17)EBRT 3D conformal (*n*)29 (83)29 (83)6 (17)BT IC only (*n*)4 (14)4 (16)0BT IC/interstitial31 (86)21 (84)10 (100)**Surgical LN staging**Yes26 (74)20 (80)6 (60)**Response rate at initial treatment**Complete25 (71)18 (72)7 (70)Partial10 (29)7 (28)3 (30)**Type of recurrence**Local/pelvic7 (20)5 (20)2 (20)Distal20 (57)13 (52)7 (70)Combination8 (23)7 (28)1 (10)**Pelvic minor intervention/surgery/biopsy after RecCC**Yes17 (49)12 (48)5 (50)No18 (51)13 (52)5 (50)**Response rate (to treatment for recurrence)**Complete7 (20)5 (20)2 (20)Partial5 (14.3)2 (8)3 (30)Stable disease4 (11.4)3 (12)1 (10)Progressive disease15 (42.9)11 (44)4 (40)Unknown4 (11.4)4 (16)0Median follow-up from recurrence (months)11 (0--50)11 (0--50)11 (5--28)Median follow-up from recurrence to event (months)8 (2--27)11 (2--20)8 (5--27)Median follow-up from diagnosis (months)26 (5--87)22 (5--87)38 (15--48)Alive with no evidence of disease5 (14.3)4 (16)1 (10)Alive with stable disease7 (20.0)4 (16)3 (30)Alive with progressive disease6 (17.1)4 (16)2 (20)Died intercurrently1 (2.9)01 (10)Died of cancer16 (45.7)13 (52)3 (30)*CHT *chemotherapy,*BEV *bevacizumab, *ECOG* Eastern Cooperative Oncology Group, *GI* gastrointestinal, *EBRT* external beam radiotherapy, *IMRT* intensity-modulated radiotherapy, *VMAT* volumetric-modulated arc therapy, *LN* lymph node, *RecCC* recurrent cervical cancer, *BT IC* intracavitary only brachytherapy

Table [2](#Tab2){ref-type="table"} provides treatment details of the therapy at first diagnosis and the number of events analysed according to the type of treatment at recurrence. No statistically significant difference in radiation dose (90.4 Gy vs. 89.4 Gy, *p* = 0.353) or number of CHT cycles at RecCC (5.1 vs. 6.4, *p* = 0.403) was observed between treatment groups.Table 2Treatment characteristics at the time of recurrence, dose--volume parameters (DVH) at the time of the initial definitive treatment and number of events based on the type of treatment for recurrent diseaseVariableCHT (*n* = 25)CHT +BEV (*n* = 10)*Fistulae*Total2 (8%)4 (40%)Rectovaginal21Vesicovaginal03*Mean (SD) no. of treatment cycles*CHT cycles5.1 (1.9)6.4 (4.5)BEV cycles--5.4 (3.6)*BT application type*IC40IC/IS2110*Radiation dose (Gy)*Mean D~90~ HRCTV90.4 (7.6)89.4 (5.7)Mean D~0.1cc~ rectum73.5 (11.3)73.1 (8.5)Mean D~2cc~ rectum63.6 (7.7)63.4 (6.9)Mean D~0.1cc~ sigmoid78.0 (13.9)80.0 (7.2)Mean D~2cc~ sigmoid64.7 (7.8)66.7 (5.8)Mean D~0.1cc~ bladder100.3 (13.3)100.5 (7.7)Mean D~2cc~ bladder79.8 (8.4)82.4 (6.0)Mean D~0.1cc~ bowel58.5 (29.5)65.4 (37.4)Mean D~2cc~ bowel52.6 (26.3)55.1 (30.1)*CHT *chemotherapy,*BEV *bevacizumab,*BT* brachytherapy, *HRCTV *high-risk clinical target volume, *D90* dose to 90% of the HRCTV, *SD* standard deviation, *IC* intracavitary only, *IC/IS* intracavitary and interstitial brachytherapy, *D2cc* dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)

A total of six fistulae were recorded (patient tumour and treatment details in Table [3](#Tab3){ref-type="table"}: P1-6). In the CHT+BEV group, a significantly higher rate of fistula formation (4/10 patients, 40%) was observed compared to the CHT only group (2/25 patients, 8%; *p* = 0.043).Table 3Tumour and treatment characteristics of the patients with events (fistula formation)Patient no. (P1--6)FIGO stageN statusTumour width at BT (mm)Applicator type at BTD~90~ HRCTV (Gy)D~0.1cc~ rectum (Gy)D~2cc~ rectum (Gy)D~0.1cc~ bladder (Gy)D~2cc~ bladder (Gy)Complete remission after definitive treatmentType of first recurrenceRecurrence therapyType of fistula (grade)Biopsy cervix interventions or pelvis surgery after recurrenceType of intervention1IIIBpN080Interstitial88.4736111192NoPersistent local diseaseCHT + BEVG2 vesicovaginalYesRepeated ureter stenting\
Nephrectomy2IIBpN060Interstitial9679699584YesSystemicCHT + BEVG3 rectovaginalYesMajor pelvic surgery\
Nephrectomy3IIIBpN150Interstitial9374669175YesLocalCHTG3 rectovaginalNoPelvic re-irradiation4IIIBcN150Interstitial93797010685NoPersistent local + systemic diseaseCHT + BEVG2 vesicovaginalYesRepeated ureter stenting5IIBcN140Interstitial84.3857010683YesSystemicCHTG3 rectovaginalYesBiopsy posterior vaginal wall6IIIBpN135Interstitial97.679649875YesSystemicCHT + BEVG3 vesicovaginalYesRepeated\
ureter stenting*CHT *chemotherapy,*BEV *bevacizumab,*BT* brachytherapy, *HRCTV* high-risk clinical target volume, *FIGO *Federation of Gynecology and Obstetrics, *D90* dose to 90% of the HRCTV, *D0.1cc* dose to 0.1cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder), *D2cc* dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)

GU fistula formation was noticed only in the CHT+BEV group (3/10 patients), of which two were grade 2 and one was grade 3 requiring surgical intervention \[[@CR16]\]. Additionally, a grade 3 rectovaginal fistula was documented in this group (P2). In the CHT only group, both events were rectovaginal fistula grade 3. For all patients with G3 rectovaginal fistula a functional colostomy was performed. For the G3 GU fistula, an ileal conduit was necessary.

At the time of recurrence, 2 patients had persistent local disease (incomplete remission), 1 patient had local recurrence (which was treated with palliative re-irradiation) and 3 patients had systemic recurrence (Table [3](#Tab3){ref-type="table"}).

All 6 patients with fistula formation had undergone an invasive procedure or palliative pelvic radiation prior to or during the systemic palliative treatment (Table [3](#Tab3){ref-type="table"}). In the CHT group the events occurred subsequent to a posterior vaginal wall biopsy (P5) and after pelvic re-irradiation (P3). In this group, a further 10 of the remaining 23 patients had undergone an invasive procedure but did not develop fistula (Table [1](#Tab1){ref-type="table"}). In the CHT+BEV group, 4/4 patients with events (100%) had undergone at least a minimally invasive procedure (i. e. ureter stenting) and only 1/6 patients (17%) did not develop an event after an invasive procedure.

We found no association between radiation dose to the target or the reported DVH parameters for OARs and the rate of fistula (Table [4](#Tab4){ref-type="table"}).Table 4Mean radiation dose for HRCTV and OARs according to fistula status (dose -- volume parameters \[DVH\] patients and Gy)VariableFistulaNo fistula*p*-valueCHT (absolute number of cycles)2230.043^a^CHT + BEV (absolute number of cycles)46--Mean HRCTV D~90~ (%)92.1 (5.0)89.7 (7.4)0.353^b^Mean D~0.1cc~ rectum (%)78.0 (4.6)72.4 (11.1)0.060^b^Mean D~2cc~ rectum (%)62.8 (7.8)66.9 (3.6)0.066^b^Mean D~0.1cc~ bladder (%)100.2 (12.6)101.2 (7.9)0.806^b^Mean D~2cc~ bladder (%)82.1 (6.7)80.2 (8.1)0.551^b^Mean D~0.1~ sigmoid (%)69.3 (12.5)80.5 (11.6)0.084^b^Mean D~2cc~ sigmoid (%)59.4 (8.8)66.5 (6.4)0.108^b^Mean D~0.1~ bowel (%)69.2 (20)57 (16)0.193^b^Mean D~2cc~ bowel (%)58 (9)53 (10)0.278^b^No. of CHT cycles (%)5.2 (2.2)5.6 (3.0)0.715^b^No. of BEV cycles (%)3.8 (1.7)6.5 (4.3)0.200^b^*CHT *chemotherapy,*BEV *bevacizumab,*HRCTV* high-risk clinical target volume, *D90* dose to 90% of the HRCTV, *OAR* organ at risk, *D0.1cc* dose to 0.1cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder), *D2cc* dose to 2cc volume of the respective organ (i.e: rectum, sigmoid, bowel, bladder)^a^χ^2^ test^b^ *t*-test

Within the cohort, median follow-up was 11 months (range 0--50 months) and overall survival time from the date of diagnosis of RecCC was 8 months (2--27 months) and 26 months (5--87 months) from diagnosis of primary disease. Fistula formation had no significant impact on overall survival (*p* = 0.317).

Discussion {#Sec12}
==========

In this study, patients receiving a combination of CHT and BEV for the treatment of RecCC had a significantly higher risk for fistula formation than patients receiving CHT alone (40 vs. 8%). We observed a notably higher rate of GU fistula in patients treated with CHT+BEV (30% vs. none). The rate of rectovaginal fistula was similar in the two groups (10 vs. 8%).

Previously published studies reported an overall fistula (\>grade 2) formation rate of 8.6% (GI vaginal) and 3.2% GI perforation in 218 patients with preliminary metastatic or recurrent cervical cancer treated in the CHT+BEV arm \[[@CR17]\] of the GOG 240 study (first data freeze). Furthermore, the rate of fistula (any grade) formation was even higher (12.6%) during CHT+BEV treatment if only patients with prior radiochemotherapy were considered \[[@CR11]\]. Overall, GOG 240 reported an increased incidence of 6% of fistula formation (second data freeze) \[[@CR9]\]. It is not clear how many patients had received definitive radiochemotherapy including IGABT in the GOG 240 cohort. In our cohort, only patients who received definite IGABT plus radiochemotherapy as initial treatment were included. Therefore, our cohort is the first one comparing CHT and CHT+BEV in LACC patients previously treated with definitive radiochemotherapy and IGABT.

All patients who developed fistulae in our cohort had undergone a minor intervention (5/6, 83%; repeated ureter stenting, biopsy or pelvic re-irradiation) or a major pelvic surgery (1/6, 17%). This is in accordance with the observation of Feddock el al. \[[@CR19]\], who associated pelvic radiation and invasive procedures with 8.2% fistula formation, even in the absence of CHT ± BEV. In the CHT group, 43% (10/23) of the non-event patients had undergone an intervention, while in the CHT+BEV only group, 17% (1/6) had undergone an invasive pelvic procedure and did not develop a fistula. This may suggest that BEV in the presence of an invasive pelvic procedure may trigger GU fistula formation. There are case reports in literature suggesting that a combination of perioperative BEV administration and an invasive procedure could result in fistula formation. Aortooesophageal fistula rupture or colovesical fistula during treatment including BEV due to metastatic colorectal cancer have been reported in case studies \[[@CR25]\]. One other report describes two late-onset pulmonary fistulae after resection of pulmonary metastasis from colorectal cancer following perioperative CHT with BEV \[[@CR26]\]. An increased risk of bowel perforation or fistula formation for patients with recurrent epithelial ovarian cancer treated with BEV has been observed \[[@CR24], [@CR27], [@CR28]\].

Although not statistically significant due to the limited number of patients and events, one may observe the fact that 3/6 patients with fistulae had a local recurrence (2 patients never achieved complete local remission and 1 had a local recurrence).

We could not detect any association between comorbidities, radiation dose, performance status or previously performed bowel surgery prior to the diagnosis of RecCC and a higher rate of fistula formation. Our findings are in accordance with previously published reports \[[@CR20]\]. In a study including 30 patients with FIGO stage IVA (with bladder or/and rectal infiltration) undergoing radiochemotherapy, the 5‑year fistula-free survival rate was 64%, but no prognostic variables were identified. Although all the patients in the CHT +BEV group underwent interstitial IGABT as opposed to 84% in the CHT group, the use of interstitial implants is not statistically correlated to the occurrence of fistula when BEV is added to the treatment of RecCC (*p* = 0.18). Moreover, recent literature shows that primarily use of advanced IGABT, especially interstitial implants, does not increase late toxicity when compared to intracavitary therapy only \[[@CR18]\].

Recent studies suggest that only intermediate- and high-risk RecCC patients show a survival benefit when receiving CHT+BEV \[[@CR21]\]. These patients have 2--3 (intermediate-) and 4--5 (high-risk) risk factors from: black race, performance status 1, pelvic disease, prior cisplatin and progression-free interval \<365 days. Hence, patient selection is crucial with respect to side effects and complications. Several approaches were performed to identify biomarkers to predict the effect of BEV on an individual basis \[[@CR22]\]. However, no predictive biomarker has been established thus far.

CHT+BEV is administered to RecCC patients without curative intent. The quality of life in this palliative setting is of particular importance and should have a substantial influence on the selection of therapy. Interestingly, while GOG 240 reported an increased rate of fistula in the CHT+BEV group, the quality of life was not decreased in this group. Other reports show that fistula formation leads to a substantial reduction in quality of life \[[@CR23]\]. Therefore, patient-reported outcomes, as used in GOG 240, might not be appropriate to determine the detrimental effect of fistula formation on quality of life.

Based on our observations, we suggest that when facing persistent disease or local recurrence, with or without systemic disease, caution should be used in prescribing CHT+BEV. This combination should be offered only after thoroughly informing the patients about the high probability of developing fistula, especially GU fistula. Prudence should also be used when facing ureteral stent change or other pelvic interventions, which are common in patients with RecCC.

Admittedly, the shortcomings of this study have to be considered. This was a retrospective data analysis of a small patient cohort from a single institution. The limited number of patients included in this report impaired statistical analysis and multivariate models were not feasible. However, given the lack of published data and increasing number of patients who are possibly candidates for this treatment, we want to raise awareness about the potential risks of using BEV in addition to CHT in the setting of pelvic RecCC and related interventions.

Conclusion {#Sec13}
==========

Until larger studies are available, based on our observations in this small cohort, and given the overall survival benefit \[[@CR9]\], CHT+BEV should probably be offered mainly to patients with local control and systemic recurrences. Future clinical studies are required to identify predictive and prognostic factors for fistula formation, in order to improve patient selection for CHT+BEV in the setting of RecCC.
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